Add to ORKGBackground:Recentmeta-analyses have raised the pos-sibility that rosiglitazone maleate may increase the risk of ischemic cardiovascular events, whereas pioglitazone hydrochloride could not be linked to such a risk.We com-pared cardiovascular outcomes andmortality between pa-tients initiating pioglitazone vs rosiglitazone therapy. Methods: We assembled an inception cohort of Medi-care beneficiaries older than 65 years with state-sponsored prescription drug benefits who had diabetes mellitus and initiated treatmentwith rosiglitazone or pio
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...
Objective To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglita...
Summary Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulf...
OBJECTIVE: To compare the risk of acute myocardial infarction, heart failure, and death in patients ...
Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and m...
BackgroundStudies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (CVD...
To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events a...
[[abstract]]Background and objective: Concern has been expressed over the cardiovascular risks assoc...
Background: Recent studies have raised concerns about risk of heart failure (HF) in type 2 diabetic...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events a...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...
Objective To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglita...
Summary Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulf...
OBJECTIVE: To compare the risk of acute myocardial infarction, heart failure, and death in patients ...
Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and m...
BackgroundStudies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (CVD...
To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events a...
[[abstract]]Background and objective: Concern has been expressed over the cardiovascular risks assoc...
Background: Recent studies have raised concerns about risk of heart failure (HF) in type 2 diabetic...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events a...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...
Objective To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglita...
Summary Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulf...